# "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

> **NCT06800404** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hope Biosciences Research Foundation** · enrollment: 10 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis (RRMS)
- Multiple Sclerosis

## Interventions

- **DRUG:** Autologous HB-adMSCs

## Key facts

- **NCT ID:** NCT06800404
- **Lead sponsor:** Hope Biosciences Research Foundation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-02
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06800404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06800404, ""HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06800404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*